G- oder K- Strophanthin

This channel provides evidence-based, clinically oriented information about G- and K-Strophanthin—two cardiac glycosides historically used for heart failure and arrhythmias. Though largely superseded by digoxin in modern Western medicine, strophanthin derivatives retain relevance in specific contexts: K-Strophanthin (k-strophanthoside) was used intravenously for acute decompensated heart failure, while G-Strophanthin (ouabain-like compound from Strophanthus gratus) has been studied for its rapid onset, short half-life, and potential advantages in renal impairment. The channel explores pharmacology, historical usage in European cardiology (especially Germany and Austria), comparative efficacy vs. digoxin, safety profiles, dosing nuances, and emerging research on endogenous ouabain-like compounds and their role in hypertension and sodium regulation. It also addresses common misconceptions, outdated protocols, and regulatory status—clarifying why strophanthin is not FDA-approved but remains available in some EU countries under special access or as a magistral preparation. Content draws from peer-reviewed journals, historical clinical trials (e.g., 1950s–70s German studies), pharmacovigilance data, and expert cardiologist commentary. The target audience includes healthcare professionals (cardiologists, pharmacists, internists), medical researchers, integrative physicians exploring legacy therapeutics, and informed patients seeking deeper understanding of alternative cardiac agents. While not promoting off-label use, the channel emphasizes rigorous scientific context, contraindications (e.g., ventricular tachycardia, hyperkalemia), and the critical importance of therapeutic drug monitoring. All material is presented with transparency about evidence quality—distinguishing robust clinical data from anecdotal reports or outdated practice.